Celgene International Sárl Release: Updated Results of Phase III Study Evaluating Continuous REVLIMID(R) Therapy in Newly Diagnosed Multiple Myeloma

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented during the European Haematology Association’s annual congress in Barcelona, Spain.